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AbstrAct
Introduction Acute kidney injury (AKI) affects more than 
50% of critically ill patients. The formation of calcitriol, 
the active vitamin D metabolite, from the main inactive 
circulating form, 25-hydroxyvitamin D (25(OH)D), occurs 
primarily in the proximal renal tubules. This results in 
a theoretical basis for reduction in levels of calcitriol 
over the course of an AKI. Vitamin D deficiency is highly 
prevalent in critically ill adults, and has been associated 
with increased rates of sepsis, longer hospital stays and 
increased mortality. The primary objective of this study is 
to perform serial measurements of 25(OH)D and calcitriol 
(1,25(OH)
2D), as well as parathyroid hormone (PTH) and 
fibroblast growth factor 23 (FGF23) levels, in critically 
ill adult patients with and without AKI, and to determine 
whether patients with AKI have significantly lower vitamin 
D metabolite concentrations. The secondary objectives are 
to describe dynamic changes in vitamin D metabolites, 
PTH and FGF23 during critical illness; to compare vitamin 
D metabolite concentrations in patients with AKI with and 
without renal replacement therapy; and to investigate 
whether there is an association between vitamin D status 
and outcomes.
Methods and analysis 230 general adult intensive care 
patients will be recruited. The AKI arm will include 115 
critically ill patients with AKI Kidney Disease Improving 
Global Outcome stage II or stage III. The comparison group 
will include 115 patients who require cardiovascular 
or respiratory support, but who do not have AKI. Serial 
measurements of vitamin D metabolites and associated 
hormones will be taken on prespecified days. Patients will 
be recruited from two large teaching Trusts in England. 
Data will be analysed using standard statistical methods.
Ethics and dissemination Ethical approval was obtained. 
Upon completion, the study team will submit the study 
report for publication in a peer-reviewed scientific journal 
and for conference presentation.
Trial registration number NCT02869919; Pre-results.
IntroductIon
Vitamin D deficiency is common, affecting 
25% of the general UK adult population 
in summer and up to 30%–40% in winter 
months.1 There is increasing awareness that 
vitamin D deficiency is associated with a 
number of important health consequences. 
The role of vitamin D metabolites in calcium 
homeostasis and the regulation of bone 
metabolism is well characterised. In the last 
decade it has been recognised that vitamin D 
status also impacts on infectious, immunolog-
ical, neurological, cardiovascular, endothelial 
and respiratory disorders.2–5 25-Hydroxyvi-
tamin D, termed 25(OH)D, is the main 
circulating metabolite of vitamin D and 
serves as a marker for evaluation of vitamin 
D status.1 Generally, although not universally, 
accepted cut-offs for defining vitamin D defi-
ciency and severe deficiency are 25(OH)D 
levels of 50 nmol/L and 30 nmol/L, respec-
tively.2 5
Intensive care units (ICUs) worldwide have 
reported vitamin D deficiency rates ranging 
from 60% to 100%.5 The causes may predate 
admission, or be a consequence of critical 
illness, interventions or therapies.5 25(OH)
D concentrations of <50 nmol/L are asso-
ciated with an increased rate of sepsis, a 
longer length of hospital stay and increased 
mortality both in-hospital and at 30 days in 
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Protocol
Strengths and limitations of this study
 ► Measurement of vitamin D concentrations and 
associated proteins over the course of critical illness 
in a non-interventional study.
 ► Serial measurements will be undertaken to describe 
dynamic changes.
 ► Inclusion of a heterogeneous intensive care unit 
patient cohort, including those receiving renal 
replacement therapy, with acute kidney injury of any 
aetiology.
 ► Blood sampling is scheduled once per day on day 
0, day 2, day 5 and at critical care discharge. As 
vitamin D levels have been found to vary over a 24-
hour period, this may not fully describe vitamin D 
status.
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Figure 1 Outline of the conversion of inactive 25(OH)
D to active 1,25(OH)2D by renal CYP27B1, and the 
influence of FGF23 and PTH. Extrarenal autocrine and 
paracrine production pathways are not shown. 25(OH)D, 
25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 
Ca2+, calcium; FGF23, fibroblast growth factor 23; PO4
2−, 
phosphate; PTH, parathyroid hormone; VDBP, vitamin D 
binding protein.
this population.3 6–9 The role for supplementation remains 
unclear. The largest randomised controlled study found 
an in-hospital mortality benefit only in a predefined 
subgroup of participants with vitamin D concentrations 
of <30 nmol/L after administration of a high dose of 
enteral cholecalciferol.10
Availability of active vitamin D metabolites at tissue 
level depends mainly on the relationship between 
biologically inert 25(OH)D and the active form, 1,25-dihy-
droxyvitamin D (1,25(OH)2D), as well as the actions of 
parathyroid hormone (PTH) and fibroblast growth factor 
23 (FGF23), and the availability of vitamin D binding 
protein (VDBP).11 (figure 1) The biotransformation of 
25(OH)D to 1,25(OH)2D is regulated by the enzyme 
1α-hydroxylase CYP27B1, which is produced primarily, 
but not exclusively, in the proximal renal tubules.1 Extra-
renal autocrine and paracrine production of calcitriol by 
CYP27B1 is limited by substrate concentration,12 and as 
such may be diminished in deficiency states. VDBP is a 
58 kDa protein produced by hepatic parenchymal cells, 
which transports vitamin D metabolites to target tissues 
and serves to increase the circulating half-life of vitamin 
D metabolites.1
Acute kidney injury (AKI) affects more than 50% of 
critically ill patients worldwide and is independently asso-
ciated with higher mortality, a longer length of hospital 
stay, and an increased risk of long term complications 
including bone fractures.13 14 Furthermore, a single 
episode of AKI increases the long-term risk of recurrence 
of AKI. Compared with patients who do not have vitamin 
D deficiency, vitamin D-deficient critical care patients 
have been observed to have higher rates of AKI and more 
frequent need for renal replacement therapy (RRT),15 
although any possible causal direction of this association 
remains unclear.
We hypothesise that patients with AKI have higher 
rates of vitamin D deficiency than those without AKI. If 
confirmed, our results may serve to inform the design of 
appropriate intervention trials in this patient group.
ratIonale
Patients with AKI may have altered vitamin D metabolism 
mechanisms for reasons that could include the following:
1. The kidneys generate the majority of 1α-hydroxylase 
CYP27B1 and other hydroxylases implicated in vitamin 
D metabolism, and are responsible for producing and 
regulating 1,25(OH)2D and vitamin D-dependent 
proteins.10
2. FGF23 reduces circulating 1,25(OH)2D levels. 
Concentrations of FGF23 are elevated in AKI due 
to increased production by bone and reduced 
clearance.16 17
3. Patients with AKI have lower VDBP concentrations 
than patients without AKI.16
4. Pre-existing vitamin D deficiency is highly prevalent in 
the general population and has been associated with 
the development of AKI during critical illness.1 6 15
5. 1,25(OH)2D has an elimination half-life of only 
4–15 hours.1 Circulating levels may fall over the first 
days of critical illness if renal or extrarenal production 
capability is compromised.
6. Previous studies examining the association between 
AKI and vitamin D deficiency have been inconclusive. 
A study including 200 critically ill patients revealed 
significantly lower 1,25(OH)2D concentrations at 
the time of AKI diagnosis compared with controls 
without AKI, but there were no differences in 25(OH)
D concentrations. PTH and FGF23 concentrations 
were not measured and serial measurements were not 
undertaken.8
A recent meta-analysis highlighted the lack of relevant 
studies that consider serial measurements of 25(OH)D 
and 1,25(OH)2D alongside other markers of vitamin D 
metabolism.3 Others have emphasised the importance of 
conducting intervention studies in the most appropriate 
cohort. Our aim is to understand the dynamic changes in 
vitamin D metabolite concentrations that occur over the 
course of AKI, from which the design of a future interven-
tional study could be informed.
objectIves
The primary objective is to perform serial measurements 
of 25(OH)D and 1,25(OH)2D, PTH, FGF23 and VDBP 
concentrations in critically ill adult patients with and 
without AKI, to determine whether patients with AKI have 
significantly lower vitamin D metabolite concentrations.
The following are the secondary objectives:
1. to describe the changes of 25(OH)D, 1,25(OH)2D, 
PTH and FGF23 levels during critical illness
2. to compare total and bioavailable (ie, free plus 
albumin-bound, as opposed to that bound to VDBP; 
online supplementary appendix 118 19) concentrations 
of 25(OH)D and 1,25(OH)2D in patients with AKI 
treated with and without RRT
3. to investigate whether there is an association 
between total and bioavailable vitamin D metabolite 
concentrations and outcome in critically ill patients 
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Table 1 KDIGO classification of AKI
Stage Serum creatinine (Cr) Urine output
I Rise of Cr by ≥26 µmol/L within 48 hours <0.5 mL/kg/hour for more than 6 hours
Or 50%–99% Cr rise from baseline within 7 days (1.50–1.99 × baseline)
II 100%–199% Cr rise from baseline within 7 days (2.00–2.99 × baseline) <0.5 mL/kg/hour for more than 12 hours
III ≥200% Cr rise from baseline within 7 days (≥3.00 ×  baseline) <0.3 mL/kg/hour for 24 hours or anuria for 
12 hoursCurrent Cr ≥354 µmol/L, with either rise of Cr by ≥26 µmol/L within 48 hours 
or ≥50% Cr rise from baseline within 7 days
Any requirement for renal replacement therapy
AKI, acute kidney injury; KDIGO, Kidney Disease Improving Global Outcome.
with and without AKI; outcomes reported will be 
hospital mortality, 30-day mortality and length of stay 
in ICU and in hospital
4. to explore the possible statistical interaction between 
biomarker levels and length of ICU stay.
Methods and analysIs
setting
The study will be conducted in critical care units in two 
National Health Service hospitals in the UK.
Patient selection
Adult patients admitted to a critical care unit will be 
screened for the presence of AKI, on the basis of either 
serum creatinine or urine output, as defined by the 
Kidney Disease Improving Global Outcome (KDIGO) 
consensus criteria (table 1).20 The critical care units are 
mixed medical and surgical.
The following are the criteria for inclusion into the 
study: (1) adult patient (18 years or older) admitted to a 
critical care unit and (2) presence of KDIGO AKI II or III 
for ≤36 hours (AKI arm), or presence of cardiovascular 
and/or respiratory failure requiring the use of invasive or 
non-invasive respiratory support and/or treatment with 
catecholamines (non-AKI arm), with a requirement antic-
ipated to last for longer than 24 hours.
The following are the exclusion criteria: (1) AKI stage 
I (as defined by KDIGO criteria), (2) known vitamin D 
deficiency (recorded value of <50 nmol/L on the hospi-
tal’s electronic record system, diagnosis documented on a 
hospital clinic letter, or evidence of vitamin D supplemen-
tation prescribed in primary or secondary care in the last 
3 months), (3) known vitamin D supplementation in the 
last 3 months (either as a single agent or in a combina-
tion product, including multivitamins), (4) pre-existing 
chronic kidney disease (CKD) stages 3b–5 (ie, estimated 
glomerular filtration rate <45 mL/min/1.73 m2), (5) renal 
transplant, (6) known hyperparathyroidism, (7) need 
for total parenteral nutrition (TPN), (8) anticipated life 
expectancy <48 hours, (9) haemoglobin concentration 
<70 g/L (unless a decision has been made to administer 
blood transfusion), and (10) pregnancy.
sample size calculation
Based on data from Lai et al,8 126 patients with complete 
data are required to detect a difference of 25 pmol/L in 
1,25(OH)2D concentrations between the two arms, with a 
power of 80% and at a two-tailed significance level of 5% 
(assuming an SD of 50 in each group). Interim review of 
the case report forms of a small set of patients highlighted 
an attrition rate of 40%–50% between the time of eligi-
bility screening and day 5, leading to the requirement to 
recruit a total of 230 patients to analyse at least 126 with 
complete data.
baseline data collection
The following data will be collected: age, gender, ethnicity, 
weight, height, ideal body weight, place of residence 
prior to hospitalisation, admission diagnosis, comorbid-
ities (CKD, chronic lung disease, chronic heart failure, 
coronary artery disease, cancer, chronic liver disease, 
diabetes, chronic gastrointestinal disease), premorbid 
serum creatinine concentration, C reactive protein 
(CRP), albumin, Acute Physiology and Chronic Health 
Evaluation (APACHE) II score on admission, and daily 
Sequential Organ Failure Assessment (SOFA) scores. We 
also plan to collect data on potential confounding factors, 
including daily nutritional intake, fluid balance, calcium 
and phosphate supplementation and treatment with 
extracorporeal therapy (ie, RRT and plasma exchange).
sampling
On the day of enrolment, day 5 and the day of discharge 
from the critical care unit, blood will be taken for 
measurement of 25(OH)D, 1,25(OH)2D, PTH, FGF23 
and VDBP. Samples will be taken in the morning, between 
09:00 and 12:00. In a yellow top SST vacutainer, 5.5 mL of 
blood will be collected, and 4 mL will be collected in a 
purple top EDTA vacutainer. Samples will be centrifuged 
at 3500 rpm for 10 min, then aliquots of 0.5 mL serum for 
25(OH)D, 1 mL serum for 1,25(OH)2D and 0.5 mL serum 
for VDBP will be taken from the SST tube, and 1 mL of 
plasma for PTH and 1 mL of plasma for FGF23 from the 
EDTA tube. Samples will then be stored at −70°C until 
analysis. Additional measurements of 1,25(OH)2D and 
PTH will be made on day 2 (table 2). Calcium and phos-
phate are measured routinely on a daily basis for all ICU 
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Table 2 Sampling schedule
Serum concentration Day 0 (day of enrolment) Day 2 Day 5 Day of intensive care unit discharge
25-hydroxyvitamin D √ – √ √
1,25-dihydroxyvitamin D √ √ √ √
Calcium (Ca) √ √ √ √
Phosphate (P) √ √ √ √
Parathyroid hormone √ √ √ √
Fibroblast growth factor 23 √ – √ √
Vitamin D binding protein √ – √ √
patients as part of preward round bloods, typically taken 
at 06:00. These results will be recorded.
All samples will be stored in dedicated research freezers 
until batch analysis.
25(OH)D will be measured by liquid chromatogra-
phy-mass spectrometry, with a coefficient of variation of 
7.3% for 25(OH)D2 and of 10.9% for 25(OH)D3. Total 
1,25(OH)2D will be measured by radioimmunoassay. 
FGF23 will be measured using the Immutopics Human 
FGF23 (C-Term) ELISA assay.21 VDBP will be measured 
by ELISA assay, using the Quantikine Human Vitamin D 
BP Immunoassay.22 PTH will be measured using a Roche 
automated analyser.
statistical analysis
Multiple comparisons will be performed to determine 
the difference in vitamin D metabolite concentrations 
between the two arms. The distribution of the data will 
be examined and appropriate statistical tests will be 
applied, accounting for potential confounding factors 
including age, ethnicity, CRP, calcium concentrations, 
season, severity of illness at admission using APACHE II 
scores and pattern of organ failures using SOFA scores. A 
longitudinal analysis will be presented, covering the time 
from enrolment to the date of critical care discharge, to 
describe changes in 25(OH)D, 1,25(OH)2D, FGF23 and 
PTH concentrations over the course of critical illness. An 
investigation of possible correlation between vitamin D 
metabolites and related hormones (PTH and FGF23) on 
day 0 and day 5 is planned. A subgroup analysis is planned 
for those participants receiving RRT and in patients with 
sepsis on the day of enrolment. Association between 
25(OH)D and 1,25(OH)2D concentrations and hospital 
and 30-day outcomes will be examined, as well as ICU and 
hospital length of stay.
An interim analysis is planned after recruitment of 126 
participants.
Patients who do not have AKI at enrolment but who 
go on to develop AKI during the first 5 days will not be 
included in the analysis for the primary outcome. Results 
from these patients will be analysed separately.
dIscussIon
This study aims to describe the dynamic changes 
in 25(OH)D and 1,25(OH)2D concentrations, and 
associated hormones, in a general population of critically 
unwell patients with and without AKI.
The strengths of this project are that (1) we plan to 
measure 25(OH)D and 1,25(OH)2D together with regu-
latory hormones and proteins, which will address an 
existing gap in knowledge. (2) Serial measurements will 
be undertaken to determine dynamic changes, including 
an additional measurement of 1,25(OH)2D on day 2. This 
will serve to provide data on the timing and magnitude 
of a drop in concentrations of this metabolite, which is 
predicted based on previous work23 and from the biolog-
ical basis that 1,25(OH)2D has a circulating half-life of 
only 4–15 hours.1 (3) The project is adequately powered 
to provide meaningful data.
We are aware of potential limitations, which we will 
eliminate as much as possible.
1. The high attrition rate identified in early work 
comprises participants who did not have AKI at 
enrolment, but who went on to develop AKI during 
the first 5 days of their critical care stay; patients 
who went on to meet an exclusion criterion such as 
requirement for TPN; and patients for whom a pre-
existing known vitamin D deficiency was identified 
after enrolment. The sample size was increased to 
230 to maintain power to detect a clinically significant 
difference between arms if one exists. The increase 
in sample size was approved by a national research 
ethics committee and the institutional governance 
department.
2. We plan to perform serial measurements but will only 
undertake blood sampling once a day. Blood samples 
will be collected in the morning (between 09:00 
and 12:00) on the days specified in table 2. Previous 
studies confirmed diurnal variation of 25(OH)D 
concentrations in intensive care patients over 24 hours 
with mean within-patient variation of 24.3 nmol/L 
over a 24-hour period.24 As such, single point in time 
measures may not be adequate to describe vitamin D 
status fully.
3. We plan to enrol patients with AKI independent 
of underlying aetiology. By not stratifying patients 
by aetiology of AKI, patients with a wide range of 
clinical diagnoses will be eligible for inclusion and 
the results of the study will remain generalisable. 
Stratification would, nonetheless, have been useful 
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to identify a population who may benefit most from 
supplementation in a future trial.
4. Patients prescribed vitamin D supplements in primary 
care or from secondary or tertiary care clinics at 
the host institutions can be identified and excluded 
from the study. However, patients taking vitamin D 
prescribed by other institutions or those buying over-
the-counter supplements cannot be identified in all 
cases. Medication histories do routinely prompt for 
this, acknowledging that information from relatives in 
cases where the patient cannot clarify for themselves 
may be incomplete.
5. Limited resources mean measurement of other 
associated proteins, including alpha Klotho, which is 
primarily generated by the kidneys and plays a role 
in bone mineral metabolism, is not possible. Further, 
the lack of a standardised assay to measure circulating 
Klotho precludes its measurement within this study.25 
It could, however, represent an interesting area for 
future work.
6. The equations used to describe levels of bioavailable 
vitamin D metabolites (ie, free and albumin-bound; 
online supplementary appendix 1) have not been 
validated in the critical care population, but have been 
used in several other studies that included critical 
care patients.2 3 26 27 The bioavailable vitamin D values 
reported in this study should be viewed as indicative 
estimates, as direct assay of free vitamin D metabolites 
is not possible. While measurement of concentration of 
VDBP to inform the equations in online supplementary 
appendix 1 is possible within the available resources, 
assessment of genotype is not. Lack of this information, 
which is known to affect the affinity of vitamin D 
metabolites for VDBP, is a limitation of this work.28
ethIcs and dIsseMInatIon
Full ethical approval was granted by the London — 
Camberwell St Giles National Research Ethics Committee 
on 30 March 2016.
Participants will be asked to give their consent to partic-
ipate in the study. In the event that they are unable to 
give consent for themselves, a personal consultee (eg, 
next of kin) will be contacted and informed about the 
study and asked whether the patient would have any 
objections to participating in this observational study. 
They will be asked to sign a personal consultee declara-
tion form. In case a personal consultee is not available, a 
nominated consultee (a clinician who is not connected to 
the research study) will be contacted. When the patient 
regains capacity, they will be informed about the study 
and asked to give consent to remain in the study. The 
Research Ethics Committee agreed that the study has the 
potential to benefit participants lacking capacity without 
imposing a disproportionate burden on them.
On completion, the study team will submit the study 
report for publication in a peer-reviewed scientific 
journal.
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